title: Effect of cyproterone acetate, d-norgestrel and progesterone on cells of the pars distalis of the adenohypophysis in the beagle bitch.
abstract: The effects of short-term (8 weeks) treatment with different doses of cyproterone acetate (CPA), d-norgestrel (d-N) and progesterone on cells of the pars distalis, as revealed by the immunoperoxidase technique, were studied in cycle-synchronized beagle bitches (first anoestrus). Pituitary glands from non-treated primiparous beagle bitches at the 6th and 9th week of pregnancy were also included. For immunochemical staining specific antisera to the following hormones were used: canine GH, canine PRI, porcine ACTH, bovine TSHbeta, bovine LHbeta and human FSHbeta. Morphological features of high secretory activity in GH cells were evident even after the human oral contraceptive does of CPA and d-N, and after a dose as low as 0.1 mg/kg/day subcutaneously (s.c.) of progesterone. In contrast, PRL cells did not show any significant treatment-related effects except in those animals which received the highest dose of d-N (0.5 mg/kg/day per os). In this group, as well as in all pregnant bitches, hyperplasia and hypertrophy of PRL cells were found. In the animals treated with the highest doses of CPA (4.0 mg/kg/day per os) and progesterone (42.5 mg/kg/day s.c.) as well as in pregnant bitches, ACTH/MSH and TSH cells showed marked atrophy and regressive changes. Similar morphological signs of depressed secretory activity were also observed in the cells shown to contain FSHbeta and/or LHbeta as a result of treatment with the highest dose of progesterone and at the 9th week of pregnancy. These structural responses indicate that quantitiative and/or qualitative differences may exist between progesterone, the synthetic progesterone derivative CPA and the nortestosterone type progestagen d-N with regard to their effect on pituitary hormone secretion in the beagle bitch.
mesh_terms: D000818:Animals; D003534:Cyproterone / Q000494:pharmacology*; D004285:Dogs; D004971:Estrus / Q000187:drug effects; D005260:Female; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D013006:Growth Hormone / Q000378:metabolism; D007986:Luteinizing Hormone / Q000378:metabolism; D009644:Norgestrel / Q000494:pharmacology*; D010902:Pituitary Gland / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010903:Pituitary Gland, Anterior / Q000187:drug effects; D010907:Pituitary Hormones / Q000378:metabolism; D011247:Pregnancy; D011374:Progesterone / Q000494:pharmacology*
chemical_list: D010907:Pituitary Hormones; D009644:Norgestrel; D011374:Progesterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013006:Growth Hormone; D003534:Cyproterone